ViroGates A/S

Equities

VIRO

DK0061030574

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 10:53:17 2024-05-08 EDT			5-day change	1st Jan Change
6.84 ^DKK	0.00%		+3.64%	+13.62%

05-02	ViroGates A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-15	Virogates A/S Announces the Outcome of Its Q-Submission Filing for Sobi®? Turbi Latex with the Us Food and Drug Administration	CI

ViroGates A/S Provides Revenue Guidance for the Year 2022 and 2023

June 22, 2022 at 08:38 am

ViroGates A/S provided revenue guidance for the year 2022 and 2023. For the year 2022, the company expects revenue between DKK 10 million and 13 million.

For the year 2023, the company expects revenue between DKK 17 million and 21 million.

Latest news about ViroGates A/S

ViroGates A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	05-02	CI
Virogates A/S Announces the Outcome of Its Q-Submission Filing for Sobi®? Turbi Latex with the Us Food and Drug Administration	04-15	CI
ViroGates A/S Reports Earnings Results for the Full Year Ended December 31, 2023	03-21	CI
ViroGates A/S Provides Earnings Guidance for the Year 2024	12-21	CI
ViroGates A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
ViroGates A/S Announces Positive Results from a Randomized Controlled Clinical Trial on Supar-Guided Antibody Treatment in Sepsis	23-09-22	CI
ViroGates A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-17	CI
Virogates Provides Earnings Guidance for 2023	23-08-17	CI
ViroGates A/S Announces an Agreement with Sobi for the Development of Suparnostic®	23-06-02	CI
ViroGates A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
ViroGates A/S Announces the Commercial Launch of suPARnostic POC+ Product	23-02-24	CI
ViroGates A/S Announces CE-IVD approval for suPARnostic® TurbiLatex on the Roche Diagnostics cobas® Pure and Pro instrument platforms	23-02-06	CI
Denmark's ViroGates Names New CFO	23-02-01	MT
ViroGates A/S Announces Chief Financial Officer Changes	23-02-01	CI
ViroGates A/S Revises Earnings Guidance for Full-Year 2022 and 2023	22-12-16	CI
ViroGates A/S Announces Executive Changes	22-12-06	CI
ViroGates A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
ViroGates A/S Announces the Publication of A New Study That Shows SsuPAR upar Causes Cardiovascular Disease	22-10-05	CI
ViroGates announces CE-IVD approval for suPARnostic® TurbiLatex on the Beckman Coulter AU5800 platform	22-09-23	CI
ViroGates A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-18	CI
ViroGates A/S Provides Revenue Guidance for the Year 2022 and 2023	22-06-22	CI
ViroGates A/S Announces Board Changes	22-05-30	CI
ViroGates Announces the CE-Ivd Accreditation of Its Finger-Prick Blood-Testing Product, Suparnostic® Poc+	22-05-25	CI
ViroGates A/S Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-04	CI
ViroGates A/S Announces Board Changes	22-04-28	CI

Chart ViroGates A/S

Duration

Period

More charts

Company Profile

ViroGates A/S is a Denmark-based medical technology company. Its develops a product line suPARnostic, which measures the amount of amount of soluble urokinase Plasminogen Activator Receptor protein (suPAR) in human blood. The plasma level of suPAR reflects immune activation and is increased in such infectious diseases as HIV-1-infection, malaria, tuberculosis, Streptococcus pneumonia bacteraemia, sepsis, pneumococcal pneumonia and bacterial and viral CNS infection. Also, high suPAR levels are associated with increased inflammation, disease progression and risk of mortality. Thus, measuring suPAR levels serves as a marker to determine chances for survival upon hospital admission, as well as for monitoring for prevention of disease progression and earlier intervention time point. suPARnostic has two versions: Quantitative Point of Care Quick Triage test, which serves for patient triage in acute care, and Quantitative ELISA Assay that aims at clinical routine use.

Sector

Biotechnology & Medical Research

Calendar

2024-08-14 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
VIROGATES A/S	+13.62%	6.35M
EXACT SCIENCES CORPORATION	-28.16%	10.94B
IOVANCE BIOTHERAPEUTICS, INC.	+64.64%	3.75B
GUARDANT HEALTH, INC.	-30.61%	2.27B
BGI GENOMICS CO., LTD.	-10.77%	2.25B
VERACYTE, INC.	-25.81%	1.54B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+50.38%	1.18B
SEEGENE, INC.	-2.84%	754M
CAREDX, INC	-8.67%	529M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-30.10%	469M

Bio Diagnostics & Testing